17:38:12 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-03-05 14:45:59

COPENHAGEN, Denmark, 5 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Malene Gottfredsen. Malene Gottfredsen (MSc in Pharmacy, Faculty of Pharmaceutical Sciences, University of Copenhagen) has been appointed as Product Manager at DanCann Pharma A/S.

Educated a pharmacist, Malene joins the commercial team and will be in charge of handling clinical data on products sold by DanCann Pharma. This involves close cooperation with partners and clients. Malene will be in charge of educating DanCann Pharma's sales force on the clinical aspects of the products in the market.

Malene Gottfredsen has a strong force in safety and clinical trials, with more than 10 years' experience from various settings. Malene has previously held positions at AstraZeneca PLC, Novo Nordisk A/S and Lundbeck A/S - where she has worked in a broad field from Medical Information (to HCP and patients) Safety Surveillance (Senior Specialist and Senior Advisor) and was responsible for, among other things, a Phase I project at Lundbeck and worked with the Victoza phase III-IV projects at Novo Nordisk. Malene has strong experience with the Safety Committee Chair from several projects, including at Novo Nordisk and Lundbeck.

Malene states: "I was immediately interested in working for DanCann Pharma as I felt a certain dynamic atmosphere. The potential to use cannabis in a medical setting is a growing area that I am excited to be a part of. Since joining the company, I have been able to see the purpose of my role and have already been given the opportunity to make a meaningful contribution in relation to my colleagues. I recognize how my current skills will add value to the team, and I look forward to learning more and to grow within the company."

John Morell Frellsen, CCO at DanCann Pharma: "We are happy and privileged to have had the opportunity to get Malene on board. As we work with an increasing number of research-driven and cannabinoid-derived products, Malene's background comes well into play, and she will become an invaluable asset in our further work with research organizations, clients and patients."

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com